Overview
An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.
Indication
For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
Associated Conditions
- Chickenpox
- Cytomegalovirus Retinitis
- Herpes Simplex Infections
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2016/12/28 | Phase 4 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | ||
2016/10/13 | Phase 3 | Completed | |||
2014/05/30 | Phase 4 | Completed | Cttq | ||
2010/09/13 | Not Applicable | Active, not recruiting | City of Hope Medical Center | ||
2009/09/30 | Phase 2 | UNKNOWN | University Hospital Birmingham | ||
2001/08/31 | Phase 1 | Completed | |||
2001/08/31 | Phase 2 | Completed | |||
2001/08/31 | Not Applicable | Completed | Astra USA | ||
2001/08/31 | Not Applicable | Completed | Astra USA | ||
2001/08/31 | Phase 3 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Baxter Healthcare Corporation | 43066-089 | INTRAVENOUS | 6000 mg in 250 mL | 8/28/2023 | |
| Clinigen Limited | 76310-024 | INTRAVENOUS | 24 mg in 1 mL | 6/19/2020 | |
| Fresenius Kabi USA, LLC | 63323-875 | INTRAVENOUS | 24 mg in 1 mL | 1/29/2021 | |
| Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-771 | INTRAVENOUS | 24 mg in 1 mL | 6/13/2023 | |
| Sagent Pharmaceuticals | 25021-189 | INTRAVENOUS | 24 mg in 1 mL | 4/22/2021 | |
| Clinigen Limited | 76310-024 | INTRAVENOUS | 24 mg in 1 mL | 6/19/2020 | |
| Gland Pharma Limited | 68083-389 | INTRAVENOUS | 24 mg in 1 mL | 4/24/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| FOSCAVIR foscarnet sodium 6g/250mL injection bottle | 37310 | Link Medical Products Pty Ltd T/A Link Pharmaceuticals | Medicine | A | 9/29/1992 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| VOCARVI | Sterimax Inc | 02505924 | Solution - Intravenous | 24 MG / ML | 3/30/2021 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.